natgillin/translations-raw huggingface dataset:
Effects of other medicinal products on mercaptopurine When allopurinol and Xaluprine are administered concomitantly it is essential that only a quarter of the usual dose of Xaluprine is given since allopurinol decreases the rate of metabolism of 6-mercaptopurine via xanthine oxidase. 
Pri istodobnoj primjeni alopurinola i Xaluprina, nužno je primijeniti samo četvrtinu uobičajene doze Xaluprina budući da alopurinol smanjuje brzinu metabolizma
Xaluprine contains aspartame, sodium methyl parahydroxybenzoate (E219), sodium ethyl parahydroxybenzoate (E215) and sucrose 
Xaluprine sadrži aspartam, natrijev metilparahidroksibenzoat (E219), natrijev etilparahidroksibenzoat (E215) i saharozu
Blood levels of anti-epileptic medicines may need to be monitored and doses adjusted if necessary. 
Razine antiepileptika u krvi potrebno je mjeriti te prema potrebi prilagoditi doze.
You should use this one if the total amount you have to take is less than or equal to 1 ml (each graduation of 0.1 ml contains 2 mg of mercaptopurine). 
Tu štrcaljku trebate koristiti ako je ukupna količina koju trebate uzeti veća od 1 ml (svaka graduacija od
o A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV)-associated lymphoproliferative disorders). 
Uz režim liječenja koji sadrži višestruke imunosupresive (uključujući tiopurine), može doći do smrti. o kombinacija višestrukih imunosupresiva koji se istodobno primjenjuju povećava rizik od poremećaja limfnog sustava kao posljedice virusne infekcije (limfoproliferativni poremećaji povezani s Epstein-Barrovim virusom (EBV)).
Each pack contains one bottle, an HDPE bottle adaptor and 2 polyethylene dosing syringes (a purple syringe graduated to 1 ml and a white syringe graduated to 5 ml). 
Jedno pakiranje sadrži jednu bočicu, HDPE nastavak za bočicu i 2 polietilenske štrcaljke za doziranje (ljubičastu graduiranu štrcaljku od 1 ml i bijelu graduiranu štrcaljku od 5 ml).
Each pack contains one bottle, a bottle adaptor and two dosing syringes (a purple syringe graduated to 1 ml and a white syringe graduated to 5 ml). 
Jedno pakiranje sadrži jednu bočicu, nastavak za bočicu i dvije štrcaljke za doziranje (ljubičastu graduiranu štrcaljku od 1 ml i bijelu graduiranu štrcaljku od 5 ml).
Xaluprine may be taken with food or on an empty stomach, but patients should standardise the method of administration. 
Xaluprine se može uzimati s hranom ili natašte, ali uvijek na isti način.
NAME OF THE MEDICINAL PRODUCT Xaluprine 20 mg/ml oral suspension mercaptopurine 
Uputa o lijeku: Informacije za korisnika Xaluprine 20 mg/ml oralna suspenzija merkaptopurin
Since 6-mercaptopurine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given. 
Oštećenje funkcije bubrega Budući da farmakokinetika merkaptopurina nije službeno ispitivana u osoba s oštećenjem funkcije bubrega, ne mogu se dati posebne preporuke o doziranju.
Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ. 
U bolesnika koji primaju terapiju imunosupresivima, uključujući merkaptopurin postoji povećani rizik od nastanka limfoproliferativnih poremećaja i drugih zloćudnih bolesti, posebice raka kože
STATEMENT OF ACTIVE SUBSTANCE(S) One ml of suspension contains 20 mg mercaptopurine (as monohydrate). 
Jedan ml suspenzije sadrži 20 mg merkaptopurina (u obliku hidrata).
Put on disposable hand gloves before handling Xaluprine. 
Prije rukovanja Xaluprineom obucite rukavice za jednokratnu uporabu.
Xaluprine contains mercaptopurine. 
Što je Xaluprine i za što se koristi Xaluprine sadrži merkaptopurin.
Name and address of the manufacturer(s) responsible for batch release 
PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Nova Laboratories Limited
Also contains: sodium methyl parahydroxybenzoate (E219), sodium ethyl parahydroxybenzoate (E215), potassium sorbate (E202), sodium hydroxide, aspartame (E951) and sucrose. 
Također sadrži: natrijev metilparahidroksibenzoat (E219), natrijev etilparahidroksibenzoat (E215), kalijev sorbat (E202), natrijev hidroksid, aspartam (E951) i saharoza.
- you have a condition where your body produces too little of the enzyme called TPMT 
- imate problema s bubrezima ili jetrom jer će Vaš liječnik trebati provjeriti rade li ispravno. - imate stanje u kojem Vaš organizam stvara premalo enzima zvanog tiopurin metiltransferaza jer će
Uncommon (affects less than 1 in 100 people) - mouth ulcers - inflamed pancreas - joint pain - skin rash - fever - permanent damage to the liver (hepatic necrosis) 
- kožni osip - vrućica - trajno oštećenje jetre (hepatička nekroza)
Sodium methyl parahydroxybenzoate (E219) Sodium ethyl parahydroxybenzoate (E215) Potassium sorbate (E202) Sodium hydroxide 
natrijev etilparahidroksibenzoat (E215) kalijev sorbat (E202)
Precautions). 
Moguće nuspojave).
Therefore, Xaluprine may be taken with food or on an empty stomach, but patients should standardise the method of administration. 
Stoga se Xaluprine može uzimati s hranom ili natašte, ali uvijek na isti način.
NAME OF THE MEDICINAL PRODUCT Xaluprine 20 mg/ml oral suspension 
Xaluprine 20 mg/ml oralna suspenzija
When oral anticoagulants are coadministered with 6-mercaptopurine, a reinforced monitoring of INR (International Normalised Ratio) is recommended (see section 4.5). 
International Normalised Ratio) pri istodobnoj primjeni peroralnih antikoagulansa i 6-merkaptopurina (vidjeti dio 4.5).
Hepatic impairment 
- gubitak kose
EXPIRY DATE 
Datum otvaranja
PHARMACEUTICAL FORM AND CONTENTS Oral suspension. 
Prijelaz s tableta na oralnu suspenziju i obrnuto
Hepatobiliary disorders 
Metaboliti
Open date: ______ 
Rok valjanosti:
Combination with xanthine oxidase inhibitors 
6-merkaptopurina putem ksantin oksidaze.
Xanthan gum 
Martin House
Hepatic necrosis 
Nekroza jetre
- Sensitivity to sunlight causing skin reactions 
Novotvorine uključujući limfoproliferativne poremećaje, rak kože
Renal impairment 
- upala gušterače
Safe handling 
Zbrinjavanje
Bone marrow suppression; leucopenia and thrombocytopenia 
leukopenija i trombocitopenija
32 mg Dispersible Tablet blister (alu/alu) 
32 mg tablete za oralnu suspenziju blister (alu/alu)
Strength Pharmaceutical Form 
(Zaštićeni) naziv Doza Farmaceutski Oblik
Date of first authorisation: 4th January 2017 
Datum prvog odobrenja: 4. siječanj 2017
95% confidence intervals. 
95% intervali pouzdanosti.
Children and adolescents 
Djeca i adolsecenti
[On carton only:] 
[Samo na kutiji:]
In some patients additional factor VIII was given. 
Kod nekih je bolesnika primijenjen dodatni faktor VIII.
The recommended dose regimens are as follows: 
Preporučeni režimi doziranja su slijedeći:
Other corticosteroids: interaction not studied. 
Ostali kortikosteroidi: interakcije nisu ispitane.
Ask your pharmacist how to throw away any medicines you no longer use. 
Pitajte svog ljekarnika kako baciti lijekove koje više ne koristite.
The mean treatment duration was 58.4 weeks. 
Srednje trajanje liječenja bilo je 58,4 tjedana.
Other forms of this medicine may be more suitable for children: ask your doctor or pharmacist. 
Drugi oblici ovog lijeka mogu biti prikladniji za djecu: pitajte svog liječnika ili ljekarnika.
[On carton only:] Open date: __________ 
[Samo na kutiji:] Datum otvaranja: __________
Based on a normal approximation of the difference in % response c 
Na temelju normalne aproksimacije razlike u % odgovora.
CARTON (BLISTERS AND BOTTLES) 
KUTIJA (BLISTERI I BOCE)
However, only limited data were available in patients above the age of 65 year. 
Međutim, za bolesnike iznad dobi od 65 godina bili su dostupni samo ograničeni podaci.
If you have chronic hepatitis B or C infection, your doctor should check your blood tests more often because you have an increased chance of developing liver problems. 
Ako imate infekciju kroničnim hepatitisom B ili C, liječnik Vam češće treba provjeravati krvnu sliku, jer imate povećanu mogućnosti razvoja tegoba s jetrom.
Due to a decrease in the exposure (AUC) of darunavir by 40%, appropriate doses of the combination have not been established. 
Zbog smanjene izloženosti (AUC) darunaviru za 40%, primjerene doze kombinacije nisu ustanovljene.
If prescribed darunavir twice daily the child must take one dose in the morning, and one dose in the evening. 
Ako je darunavir propisan dva puta na dan dijete mora uzeti jednu dozu ujutro, a jednu dozu navečer.
Your doctor may evaluate how severe your liver disease is before deciding if you can take darunavir. 
Liječnik može procijeniti koliko je teška Vaša bolest jetre prije nego što odluči možete li uzimati darunavir.
Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (frequency cannot be estimated from the available data). 
Kategorije učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
These EC50 values are well below the 50% cellular toxicity concentration range of 87 µM to > 100 µM. 
Te vrijednosti EC50 prilično su ispod 50% raspona koncentracija stanične toksičnosti od 87 µM do > 100 µM.
There are some medicines that you must not combine with darunavir. 
Postoje neki lijekovi koje ne smijete kombinirati s darunavirom.
Exposure in plasma, liver and brain was considerably higher than in adult rats after comparable doses in mg/kg between days 5 and 11 of age. 
Izloženost u plazmi, jetri i mozgu, bila je značajno viša nego kod odraslih štakora, nakon usporedivih doza u mg/kg između 5. i 11. dana starosti.
People taking darunavir may still develop infections or other illnesses associated with HIV infection. 
Osobe koje uzimaju darunavir i dalje mogu razvijati infekcije ili druge bolesti povezane s HIV infekcijom.
- Tell your doctor immediately if you notice any symptoms of infection (for example enlarged lymph nodes and fever). 
- Odmah upozorite liječnika ako uočite bilo kakve simptome infekcije (na primjer, povećane limfne čvorove i vrućicu).
Studies in animals do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Ispitivanja na životinjama ne pokazuju izravne štetne učinke s obzirom na trudnoću, embrio/fetalni razvoj, porod ili postnatalni razvoj (vidjeti dio 5.3).
Infrequently a rash may become severe or potentially life-threatening. 
Rijetko, osip može postati težak ili potencijalno opasan po život.
At least 3 oxidative metabolites of darunavir have been identified in humans; all showed activity that was at least 10-fold less than the activity of darunavir against wild type HIV. 
Ustanovljena su najmanje 3 oksidativna metabolita darunavira kod ljudi; svi su pokazali aktivnost koja je bila najmanje 10 puta manja od aktivnosti darunavira protiv divljeg tipa HIV-a.
- Take darunavir with food. 
- Darunavir uzimajte s hranom.
For blisters with plastic on one side and aluminium on the other: Do not store above 25°C. 
Za blistere s plastičnom folijom s jedne strane i aluminijskom folijom s druge strane: Ne čuvati na temperaturi iznad 25 °C.
Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX 
Podtipovi A1, D, F1, G, K, CRF02_AG, CRF12_BF i CRF06_CPX.
These are mentioned above under the heading ‘Do not combine Darunavir Mylan with any of the following medicines:' 
Navedeni su gore pod naslovom „Nemojte kombinirati lijek Darunavir Mylan ni s jednim od sljedećih lijekova“.
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Darunavir Mylan. 
Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete lijek Darunavir Mylan.
In juvenile rats receiving darunavir up to days 23-26, increased mortality was observed with convulsions in some animals. 
Kod mladih štakora koji su primali darunavir do 23-26 dana života, primijećen je povećani mortalitet s konvulzijama u nekih životinja.
- The child must take the appropriate doses of darunavir and ritonavir two times per day or once a day. 
- Dijete mora uzimati odgovarajuće doze darunavira i ritonavira dva puta na dan ili jedanput na dan.
The following patient populations were evaluated (see section 5.1): 
U nastavku je navedena populacija bolesnika koja je bila procijenjena (vidjeti dio 5.1):
The total mean treatment duration for subjects was 95.3 weeks. 
Ukupna srednja vrijednost trajanja liječenja ispitanika bila je 95,3 tjedana.
After a 400/100 mg 
Nakon doze od 400/100 mg
No pharmacokinetic data are available in patients with severe hepatic impairment. 
Nisu dostupni farmakokinetički podaci za bolesnike s teškim oštećenjem jetre.
Other medicines and Darunavir Mylan Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. 
Drugi lijekovi i Darunavir Mylan Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products. 
U slučaju istodobne antivirusne terapije za hepatitis B ili C, potrebno je slijediti relevantne Upute o lijeku koje postoje za te lijekove.
Darunavir has only been used in limited numbers of patients 65 years or older. 
Darunavir je primjenjivan samo kod ograničenog broja bolesnika u dobi od 65 godina ili starijih.
For blisters with aluminium on both sides: This medicine does not require any special storage conditions. 
Za blistere s aluminijskom folijom s obje strane: ovaj lijek ne zahtijeva posebne uvjete čuvanja.
Cobicistat is not indicated for use in twice daily regimens or for use in the paediatric population. 
Kobicistat nije indiciran za primjenu u režimu doziranja dva puta na dan ili za primjenu u pedijatrijskoj populaciji.
The effects of darunavir might be reduced if you take any of the following products. 
Učinci darunavira mogu se smanjiti ako uzimate bilo koji od sljedećih lijekova.
Dose-related increases in the incidences of hepatocellular adenomas and carcinomas were observed in males and females of both species. 
S dozom povezana povišenja incidencije hepatocelularnog adenoma i karcinoma bilo je opaženo kod mužjaka i ženki obje vrste.
- Tell your doctor if you are allergic to sulphonamides (e.g. used to treat certain infections). 
- Upozorite liječnika ako ste alergični na sulfonamide (upotrebljavaju se npr. za liječenje nekih infekcija).
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations. 
Povišenje doze ritonavira od one preporučene u dijelu 4.2, nije imalo značajan učinak na koncentracije darunavira.
Psychiatric disorders Common abnormal dreams 
Psihijatrijski poremećaji često nenormalni snovi
If you belong to this age group, please discuss with your doctor if you can use Darunavir Mylan. 
Ako pripadate toj dobnoj skupini, molimo Vas da s liječnikom razmotrite smijete li uzimati lijek Darunavir Mylan.
- The child must swallow the tablets with a drink such as water or milk. 
- Dijete mora progutati tablete s pićem poput vode ili mlijeka.
Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitors, ATC code: J05AE10. 
Farmakoterapijska skupina: Antivirusni lijekovi za sistemsku primjenu, inhibitori proteaze, ATK oznaka: J05AE10.
Do not combine Darunavir Mylan with any of the following medicines If you are taking any of these, ask your doctor about switching to another medicine. 
Nemojte kombinirati lijek Darunavir Mylan ni s jednim od sljedećih lijekova Ako uzimate neki od navedenih lijekova, pitajte svog liječnika o prebacivanju na drugi lijek.
- Tell your doctor if you have had problems with your liver before, including hepatitis B or C infection. 
- Upozorite liječnika ako ste prije imali tegobe s jetrom, uključujući zarazu virusom hepatitisa B ili C.
Population pharmacokinetic analysis showed a slightly higher darunavir exposure (16.8%) in HIV infected females compared to males. 
Analiza populacijskih farmakokinetičkih podataka pokazala je neznatno višu izloženost darunaviru (16,8%) kod HIV-om inficiranih žena u usporedbi s muškarcima.
The increased exposure was likely at least partly due to immaturity of the drug-metabolising enzymes in juvenile animals. 
Izloženost je vjerojatno povećana barem djelomično i zbog nerazvijenih enzima koji metaboliziraju lijek kod mladih životinja.
For young children unable to swallow tablets, more suitable formulations containing darunavir should be checked for their availability. 
Za malu djecu koja ne mogu progutati tablete, treba provjeriti dostupnost prikladnijih formulacija koje sadrže darunavir.
angioedema, pruritus, urticaria drug reaction with eosinophilia and systemic symptoms*, Stevens-Johnson syndrome* 
angioedem, pruritus, urtikarija reakcija na lijek s eozinofilijom i sistemskim simptomima*, Stevens-Johnsonov sindrom*
Maximum plasma concentration of darunavir in the presence of low dose ritonavir is generally achieved within 2.5-4.0 hours. 
Maksimalna koncentracija darunavira u plazmi uz prisustvo niske doze ritonavira općenito se postiže unutar 2,5-4,0 sata.
Administration of darunavir did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats. 
Primjena darunavira nije uzrokovala statistički značajno povišenje incidencije bilo koje druge benigne ili maligne neoplazme kod miševa i štakora.
The clinical relevance of this increase is unknown therefore, darunavir should be used with caution. 
Klinički značaj ovog povišenja nije poznat, stoga se darunavir mora primjenjivati s oprezom.
If you take more Darunavir Mylan than you should Contact your doctor, pharmacist or nurse immediately. 
Ako uzmete više lijeka Darunavir Mylan nego što ste trebali Odmah kontaktirajte svog liječnika, ljekarnika ili medicinsku sestru.
(Rifabutin is an inducer and substrate of CYP3A.) 
(Rifabutin je induktor i supstrat CYP3A.)
What Darunavir Mylan is and what it is used for 
Što je Darunavir Mylan i za što se koristi
DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens-Johnson syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported. 
DRESS (osip izazvan lijekom s eozinofilijom i sistemskim simptomima) i Stevens-Johnsonov sindrom bili su rijetko (< 0,1%) prijavljivani, a tijekom postmarketinškog iskustva prijavljene su toksička epidermalna nekroliza i akutna generalizirana egzantematozna pustuloza.
Cold form PVC/Al/OPA-Al blister pack This medicinal product does not require any special storage conditions. 
Hladno oblikovano PVC/Al/OPA-Al blister pakiranje Lijek ne zahtijeva posebne uvjete čuvanja.
α1-ADRENORECEPTOR ANTAGONIST Alfuzosin 
α1-ANTAGONIST ADRENORECEPTORA Alfuzozin
Very common side effects (may affect more than 1 in 10 people) - diarrhoea. 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - proljev.
Hence, the use of creatinine clearance as an estimate of renal elimination capacity may be misleading. 
Stoga, korištenje klirensa kreatinina za procjenu kapaciteta eliminacije bubrezima može dovesti do krivog zaključka.
Nervous system disorders Very common headache 
Poremećaji živčanog sustava vrlo često glavobolja
Tenofovir alafenamide ↔ Tenofovir ↑ 
Tenofoviralafenamid ↔ Tenofovir ↑
Midazolam (parenteral) Zoldipem 
Midazolam (parenteralni) Zoldipem
Infections and infestations Uncommon herpes simplex 
Infekcije i infestacije manje često herpes simpleks
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. 
Ako primjetite bilo koji simptom infekcije ili drugi simptom poput mišićne slabosti, slabosti koja počinje u šakama i stopalima te se širi gore prema trupu tijela, lupanja srca, tremora ili hiperaktivnosti, molimo Vas odmah obavijestite liječnika i zatražite potrebno liječenje.
Co-administration with CYP3Ametabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects. 
Istodobna primjena s kortikosteroidima koje metabolizira CYP3A ne preporučuje se osim ako potencijalna korist za pacijenta nadilazi rizik, a u tom slučaju pacijente treba nadzirati radi pojave sistemskih učinaka kortikosteroida.
Your doctor will advise you how to deal with your symptoms or whether darunavir must be stopped. 
Liječnik će Vam savjetovati što učiniti vezano uz pojavu simptoma i morate li prestati s uzimanjem darunavira.
GS-US-216-130 Week 48 
GS-US-216-130 48. tjedan
Darunavir works by reducing the amount of HIV in your body. 
Darunavir djeluje tako da smanjuje količinu virusa HIV-a u Vašem tijelu.
- Swallow the tablets with a drink such as water or milk. 
- Progutajte tablete s pićem poput vode ili mlijeka.
● For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated. 
Za liječenje HIV-1 infekcije u odraslih bolesnika prethodno liječenih antiretrovirusnom terapijom (ART), uključujući bolesnike koji su prethodno bili liječeni u znatnoj mjeri.
● For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 
Za liječenje HIV-1 infekcije u pedijatrijskih bolesnika u dobi od 3 godine i težine najmanje 15
- Unlike ritonavir, cobicistat does not have inducing effects on enzymes or transport proteins (see section 4.5). 
- Za razliku od ritonavira, kobicistat nema inducirajuće učinke na enzime ili prijenosne proteine (vidjeti dio 4.5).
<PVC/PE/PVDC-Al blister pack only> Do not store above 25°C. 
<samo za blister pakiranje PVC/PE/PVDC-Al> Ne čuvati na temperaturi iznad 25 °C.
SEDATIVES/HYPNOTICS Buspirone 
SEDATIVI/HIPNOTICI Buspiron
This cannot be administered with these 75 milligram tablets. 
To se ne može primijeniti s ovim tabletama od 75 miligrama.
Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients. 
Stoga se preporučuje kliničko praćenje, s obzirom da je kod nekih bolesnika potrebno prilagoditi terapiju održavanja.
These medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory conditions of the eyes, joints and muscles and other inflammatory conditions. 
Ti se lijekovi upotrebljavaju za liječenje alergija, astme, upalne bolesti crijeva, upalnog stanja očiju, zglobova i mišića te ostalih upalnih stanja.
Do not use this medicine after the expiry date which is stated on the carton, blister and on the bottle after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, blisteru i boci iza „Rok valjanosti“ ili „EXP“.
One darunavir dose is 
Jedna doza darunavira je
These are: - muscle pain, tenderness or weakness. 
To su: - bol u mišićima, osjetljivost na dodir ili slabost.
In rodents the target organs identified were the haematopoietic system, the blood coagulation system, liver and thyroid. 
Kod glodavaca, ciljni organi su bili hematopoetski sustav, sustav koagulacije krvi, jetra i štitnjača.
The dose of cobicistat to be used with darunavir in children less than 18 years of age has not been established. 
Doza kobicistata koja se treba uzeti uz darunavir u djece dobi mlađe od 18 godina nije ustanovljena.
Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-Odesacetyl metabolite) was increased 1.6-fold, while Cmax remained comparable. 
Osim toga, AUC zbroja aktivnih komponenti rifabutina (izvorni lijek + 25-O-desacetil metabolit) povišen je 1,6 puta, dok je Cmax ostala usporediva.